anti-Zika Virus NS1 antibody product blog
Tags: Antibody; Monoclonal Antibody; Zika Virus NS1; anti-Zika Virus NS1 antibody;
The Zika Virus NS1 n/a (Catalog #MBS6120633) is an Antibody produced from Human and is intended for research purposes only. The product is available for immediate purchase. MyBioSource\'s Zika Virus NS1 can be used in a range of immunoassay formats including, but not limited to, Suitable for use in ELISA. Other applications not tested.Optimal dilutions to be determined by the researcher. Researchers should empirically determine the suitability of the Zika Virus NS1 n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Please refer to the product datasheet for known applications of a given antibody. We\'ve tested the Human Anti-Zika Virus NS1 (Zika Virus Nonstructural Protein) with the following immunoassay(s):
ELISA (EIA) (An ELISA plate was coated with 2ug/ml of 369674/well, then blocked with 5% BSA. MBS6120633 was titrated as shown in the figure, starting from a concentration of 1ug/ml, and the detection antibody used was IgG (HRP) Goat anti-human. The substrate used was TMB (KPL).)
Testing Data (Aedes aegypti Image source: Centers for Disease Control and Prevention Publich Health Image Library.)
Testing Data (Zika rash: arm.)
Zika virus is an emerging disease that is spread by Aedes mosquitoes. The virus was first isolated in Central Africa, and has since spread to South Asia and more recently to South America. It is a member of the flavivirus family, and is structurally closely related to viruses such as Dengue Fever Virus. Outbreaks were reported in Micronesia in 2007 and in Brazil in 2015, confirming at least 13 autochthonous infections. The Zika virus outbreak in Brazil in 2016 has gained world-wide attention, and has been linked to an increasing number of microcephaly cases. In April 2016 the Centers for Disease Control, in the USA, confirmed the link between Zika virus infection of the fetus with microcephaly.
Clinically Zika virus can cause mild fever, rash, myalgia, arthralgia and headaches, with one in four infected individuals being asymptomatic. Due to similar symptoms Zika virus infected individuals can easily be mis-identified as a dengue infection and vice-versa. In addition, Zika virus has been implicated in causing microcephaly through transmission in utero. There is no vaccine or specific treatment available for Zika virus. The NS1 protein is a major non-structural protein expressed by the Zika Virus. The NS1 monomer is a glycosylated protein of ~45kD, which associates with lipids and forms a homodimer inside infected cells. It is necessary for viral replication, and is also secreted into the extracellular space as a hexameric lipoprotein particle, which is involved in immune evasion and pathogenesis by interacting with components from both the innate and adaptive immune systems, as well as other host factors. NS1 is one of the major antigenic markers for viral infection with Zika.
The antibody is designed to provide a control for assays in which human serum is tested for antibodies specific for Zika NS1 protein, which will result from the immune response following an infection with Zika virus. The antibody has been tested in ELISA using recombinant Zika NS1 protein as the target antigen.